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Abstract
The intrinsic oncolytic specificity of vesicular stomatitis virus (VSV) is currently being exploited to develop alternative
therapeutic strategies for hepatocellular carcinoma (HCC). Identifying key regulators in diverse transduction pathways that
define VSV oncolysis in cancer cells represents a fundamental prerequisite to engineering more effective oncolytic viral
vectors and adjusting combination therapies. After having identified defects in the signalling cascade of type I interferon
induction, responsible for attenuated antiviral responses in human HCC cell lines, we have now investigated the role of
cell proliferation and translation initiation. Cell cycle progression and translation initiation factors eIF4E and eIF2Be have
been recently identified as key regulators of VSV permissiveness in T-lymphocytes and immortalized mouse embryonic
fibroblasts, respectively. Here, we show that in HCC, decrease of cell proliferation by cell cycle inhibitors or siRNA-
mediated reduction of G(1) cyclin-dependent kinase activities (CDK4) or cyclin D1 protein expression, do not significantly
alter viral growth. Additionally, we demonstrate that translation initiation factors eIF4E and eIF2Be are negligible in
sustaining VSV replication in HCC. Taken together, these results indicate that cellular proliferation and the initiation phase
of cellular protein synthesis are not essential for successful VSV oncolysis of HCC. Moreover, our observations indicate the
importance of cell-type specificity for VSV oncolysis, an important aspect to be considered in virotherapy applications in
the future.
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Introduction
Hepatocellular carcinoma (HCC) accounts for the majority of
primary liver cancers in adults [1,2,3]. Potentially curative therapies
such as liver transplantation and surgical resection can be applied
only to a small percentage of patients, and while local-regional
treatments (e.g. transarterial embolization, percutaneous ethanol
injection, or radiofrequency ablation) may be beneficial for some
HCC patients, recurrence is frequent and the long-term survival rate
remains poor. Given the limited treatment options and poor
prognosis, the use of oncolytic viruses, which have the intrinsic
ability to selectively replicate in and kill cancer cells, has found
application in the treatment of primary andmetastatic liver cancers in
preclinical studies and early clinical trials [4,5,6].
Vesicular stomatitis virus (VSV), a negative-sense single-
stranded RNA Rhabdovirus, which has inherent tumor specificity
for replication due to attenuated type I interferon (IFN) responses
in most of the tumor cells, is an extremely promising oncolytic
agent for cancer treatment [7,8]. Investigation of the host-cell
determinants of permissiveness to VSV infection has become
particularly essential for the optimization of viral vectors with
enhanced oncolytic properties in HCC, while simultaneously
maintaining attenuation in the normal surrounding liver tissue,
resulting in a wider therapeutic index. In our previous studies, we
have identified impairments in the type I IFN signaling pathway,
which contributes to the high sensitivity of HCC to VSV [9]. In
addition, cell-cycle progression and eukaryotic translation initia-
tion factors (eIF4E and eIF2Be) have been reported to determine
the susceptibility of T-lymphocytes and immortalized mouse
embryonic fibroblasts (MEF) to VSV [10,11]. The block of cap-
dependent translation by rapamycin, a mTOR inhibitor, had no
appreciable effect on VSV growth in NIH 3T3 cells, but
drastically reduced viral yield in activated T-lymphocytes [10].
Consistent with the fact that cell cycle entry is linked to protein
synthesis, G0 to G1 phase transition is crucial to sustain VSV
replication in activated T-lymphocytes [10].
Activation of the AKT/mTOR signaling cascade is a common
feature in neoplastic transformation and plays a significant role in
HCC development and progression [3,12,13]. Remarkably, over-
expression of eIF4E induces rapid cell proliferation and malignant
transformation [14,15,16]. At the molecular level, eIF4E over-
expression results in the increased translation of c-myc, cyclin D1,
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and vascular endothelial growth factor, which are involved in cycle
progression and tumorigenesis [17,18,19]. Recently, eIF4E’s
oncogenic potential was ascribed to MAP kinase-interacting
kinases (MNK)-induced phosphorylation [15,19]. In addition to
its role in regulating eIF4E phosphorylation, the MNK modulate
the stability/translation of specific mRNAs and control production
of inflammatory mediators, as well as cell proliferation and
survival [19,20,21,22]. Impaired translation control by a different
mechanism, for example increased levels of the eukaryotic
initiation factor eIF2B, is also involved in permissiveness to
VSV. The immortalization process of MEFs is associated with a
dramatic increase in the levels of eIF2B epsilon subunit [11].
Contrary to primary MEFs, the corresponding immortalized cells
support highly productive VSV infection [11].
In this work, we have investigated the function of cell proliferation
and functional involvement of AKT/mTOR and MNK/eIF4E
pathways in HCC cells and their relevance in VSV oncolysis. We
used two human HCC cell lines, HepG2 and Huh-7 and the
immortalized non-neoplastic human hepatocyte (PH5CH8) cell line,
as a model to investigate the impact of cell cycle progression and
translational control on VSV replication. The results presented here
show that inhibition of cell proliferation does not affect VSV infection
in HCC and immortalized non-neoplastic hepatocytes. Furthermore,
we show that eIF4E, as well as eIF2Be initiation factors are not
essential in conferring permissiveness to VSV infection. Taken
together, our results demonstrate that the mechanisms underlying
VSV oncolysis are cell-type specific and indiscriminate generalization
could be misleading in practical applications. Moreover, our findings
address the potential use of anti-proliferative agents in combination
with VSV for more successful therapeutic outcomes in HCC
treatment.
Materials and Methods
Cell lines and primary human hepatocytes, viruses
Two human HCC cell lines (HepG2 and Huh-7), a kind gift
from Dr. Ulrich Lauer (University Hospital of Tu¨bingen), were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 1% L-
glutamine (200 mM), 1% Penicillin/streptomycin, 1% non-
essential amino acids and 1% sodium pyruvate. Immortalized
human hepatocytes (PH5CH8) were maintained in DMEM:F12
medium. All cell cultures were regularly tested for mycoplasma
contamination.
Figure 1. Immortalized human hepatocytes, PH5CH8 cell line. A) VSV growth in immortalized non-neoplastic hepatocytes (PH5CH8) was
compared to HCC cell lines and primary human hepatocytes (PHH). Cells were infected with VSV-wt and the IFN-inducer mutant VSV-M51R at an MOI
of 0.001 and titers were determined at different time-points post-infection as indicated. Data shown are the average of three independent
experiments and error bars represent standard deviation. Significance of viral titers in PHH was calculated by comparison with titers in Huh-7
(** p,0.01). B) Proliferation of the cell lines: HepG2, Huh-7 and PH5CH8. Cells were plated at the concentration of 56103 cells per well, and their
numbers were determined up to four days after plating by MTT proliferation assay. Data are representative of three independent experiments. C)
Western blot showing the expression levels of cyclin D1 and CDK4 in HepG2, Huh-7 and PH5CH8 cells compared to PHH.
doi:10.1371/journal.pone.0010988.g001
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Primary human hepatocytes (PHH) were derived from patients
(negative for HBV, HCV and HIV) that underwent surgical
resections of liver tumors according to the guidelines of the
charitable state controlled foundation Human Tissue and Cell
Research, Regensburg, Germany [23]. PHH were kept in culture
with HepatoZYME-SFM medium (GIBCO) containing 1% L-
glutamine.
Wild-type VSV (VSV-wt) and the mutant strain VSV-M51R
were generated as previously described [5,24]. Virus stocks were
produced on BHK-21 cells and stored at 280uC. Titers were
determined by plaque assay on BHK-21 cells as described (12, 13).
Luciferase assay
Dual-Luciferase Assay system (Promega) was carried out as
recommended by the manufacturer. Cells seeded in 24-well plates
were co-transfected with the IFN-b promoter-luciferase reporter
plasmids. The relative light units were normalized by co-
transfection of constitutively active Renilla luciferase and present-
ed as fold-induction respective to the basal expression level.
Twenty-four hours later, cells were mock treated or challenged
with Poly (I:C), added to the medium or transfected or were
infected with wild-type VSV or VSV mutant M51R at an MOI of
1 for 16 hours.
Western blotting
Whole-cell extracts were run on a 10% SDS-PAGE and
transferred to nitrocellulose membranes. Total cell lysates were
prepared using lysing buffer (Cell lysing buffer, Cell Signaling
Technology Inc., Danvers, MA) containing a protease and
phosphatase inhibitor cocktail. Protein concentration in the
samples was determined using the BCA protein assay kit (Pierce,
Rockville, IL). After blocking for 1 hour with 5% skim milk/
TBS-Tween, the membranes were blotted with the following
primary antibodies overnight at 4uC: Cyclin D1, CDK4, CDK2,
phospho-p70KS6, phospho-eIF4E, eIF4E, eIF2Be (Cell Signal-
ing); VSV-G (Abcam, Cambridge, UK), Actin (Sigma-Aldrich, St.
Louis, MO). After secondary staining with anti-rabbit or anti-
mouse peroxidase-conjugated Abs (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA), blots were washed three
times with TBS-Tween. Protein bands were visualised on
Amersham Hyper-Max film by the ECL chemiluminescence
Figure 2. IFN system analysis in PH5CH8 cell line. A) Fold
induction of IFN-b promoter-Luciferase reporter gene in HCC cell lines
(HepG2 and Huh-7), immortalized hepatocytes (PH5CH8) and primary
human hepatocytes (PHH). Cells were transfected with the reporter
plasmid containing the firefly luciferase gene under the control of the
IFN-b promoter. At 24 hours post-transfection, cultures were stimulated
by a second round of transfection with Poly (I:C) (T-pIC), Poly (I:C) was
added to the medium (M-pIC), or infected with VSV-wt or VSV-M51R.
IFN-luciferase activities were measured and normalized to Renilla
luciferase (RL) gene used as an internal control. Significance was
calculated by comparison with mock-treated cultures expressing basal
firefly luciferase activity (* p,0.05; ** p,0.01; ***p,0.001). B)
Interferon protection assay in PH5CH8 compared to PHH and HepG2
and Huh-7 cells as representatives for HCC. Cells were treated overnight
with 500 IU/ml of universal type I interferon (IFN) or simply mock-
treated. VSV-wt infection was performed at MOI of 1 and viral titers
were obtained 24 hr post-infection. Titers are the mean of at least three
independent experiments (* p,0.05).
doi:10.1371/journal.pone.0010988.g002
Figure 3. Cell cycle chart and cell cycle inhibitors activity.
Scheme of cell cycle inhibitors and their specificity in blocking at a
particular phase of cell cycle.
doi:10.1371/journal.pone.0010988.g003
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Figure 4. VSV replication and cell-cycle progression. A) HCC cells (HepG2 and Huh-7) and immortalized human hepatocytes (PH5CH8) were
mock-treated (DMSO) or treated with different cell-cycle inhibitors: CDK4 inhibitor (CDK4); roscovitine (Rosco); Akt inhibitor (AKT IV); Ly294002 (Ly29);
Aphidicolin (Aphid). Cultures were infected with VSV-wt at an MOI of 0.1 and viral titers were determined 24 hr post-infection by TCID 50. Data
Oncolytic VSV and HCC
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system as recommended by the manufacturer (Amersham,
Buckinghamshire, UK).
Viral growth assays
One-step growth curves of VSV-wt and M51R mutant strains of
VSV were performed on immortalized human hepatocytes
(PH5CH8), HepG2 and Huh-7 cell lines. Cells (16106/well) were
infected at an MOI of 0.01, 0.1 or 1 according to the experiment.
After adsorption for 1 hour, the monolayers were washed three
times with PBS, and fresh medium was added. Aliquots of culture
media were collected, and fresh media was added immediately at
24 hours post-infection. Viral titers were determined by TCID 50,
and each time point represents the average of triplicate
experiments. For multicycle growth curves or experiments
concerning inhibitor treatments or siRNA transfection, cells were
infected at an MOI of 0.1, and viral titers were determined at the
indicated time points post infection by TCID50. For interferon
protection assays, cells were mock-treated or incubated with
500 IU/ml of Universal type I IFN (PBL Biomedical Laboratories)
overnight and subsequently infected with VSV-wt for 24 hours.
Treatment with inhibitors and siRNA transfection
Cells were seeded at 80–90% confluency in 6-well-plates and
serum-starved (DMEM/0.5% FCS) for 36 hours. Serum-free
medium was refreshed each 12 hours. Following starvation, the
medium was replaced with DMEM/10% FCS containing DMSO or
the different inhibitors at the indicated concentration. Cultures were
pre-treated for 16 hours and virus infections were carried out in the
presence of freshly added inhibitors. Chemicals [CDK4 inhibitor
#219476 (250–500 nM); roscovitine (50 mM), AKT IV inhibitor
(500 nM), Ly294002 (20 mM), rapamycin (50 nM), aphidicolin
(2.5 mg/ml), MNK1 inhibitor (CGP57380)] were purchased from
Calbiochem-Merck (Gibbstown, NJ). For siRNA experiments,
reverse transfection was performed using DharmaFect4 (Dharmacon,
Thermo Scientific). Cells in 96 or 24 well-plates were transfected
either without siRNA or with 100 nM of scrambled siRNA or specific
siRNA according to the manufacturer instructions. siRNAs were
purchased from Dharmacon (Thermo Scientific). 48 or 72 hours
post-transfection cultures were infected with VSV-wt at an MOI of
0.1. Titers were determined at the indicated time-points post infection
by TCID50. Cell lysates from non-infected duplicates were analysed
by Western Blot to assess the efficiency of the RNA silencing.
MTT assay
HCC cells and non-neoplastic hepatocytes were seeded at the
concentration of 56103 cells per well in 96-well plates. After
24 hours, fresh medium containing the indicated inhibitor was
applied to the cells. Following an incubation of 36 hours, MTT assay
was performed according to the manufacturer instructions (Vybrant
MTT Cell Proliferation Assay Kit, Invitrogen). Cell proliferation was
calculated as percentage based on control (mock-treated) cells.
Flow cytometry
Cell cycle was analyzed by assessing the cell cycle phases
using flow cytometry (FACScalibur, using Cell Quest software;
Becton Dickinson) according to Nicoletti et al. [25]. HCC
cells and non-neoplastic hepatocytes were seeded in 10 cm plates
and treated with cycle inhibitors or siRNA as previously described.
represent the average of 3 independent experiments. B)MTT proliferation assay in mock-treated or cell cycle inhibitor-treated cells. C) Analysis of cell
cycle phases in Huh7 cells after treatment with cycle inhibitors: CDK4 inhibitor (CDK4); roscovitine (Rosco); Akt inhibitor (AKT IV); Ly294002 (Ly29);
aphidicolin (Aphid). Samples were prepared in triplicate, and representative data from three independent experiments are shown (p,0.01). Typical
FACS pattern of Huh7 cells after treatment with DMSO and LY294002 and PI staining is shown.
doi:10.1371/journal.pone.0010988.g004
Figure 5. Cell cycle inhibitors. A broader range of concentration was
tested until the appearance of cytotoxic effects. HCC cells (HepG2 and
Huh-7) and immortalized human hepatocytes (PH5CH8) were mock-
treated (DMSO) or treated with increasing concentrations of cell-cycle
inhibitors: Roscovitine; Ly294002 and aphidicolin. Cultures were
infected with VSV-wt at an MOI of 0.1 and viral titers were determined
24 hr post-infection by TCID 50. Data represent the average of 3
independent experiments.
doi:10.1371/journal.pone.0010988.g005
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Results
Immortalized human hepatocytes support VSV
replication
VSV replicates very efficiently in human HCC cell lines, while it
exhibits an attenuated phenotype in primary human hepatocytes
(PHH) [9]. We assessed the ability of VSV to grow in
immortalized hepatocytes (PH5CH8) in comparison with HCC
and PHH (Fig. 1A). Cells were infected with VSV-wt or the
mutant VSV-M51R at an MOI of 0.01, and viral titers were
determined at different time-points post infection. Recombinant
VSV-M51R contains a mutation in its matrix (M) at position 51,
which results in an IFN-inducing phenotype [26]. Both VSV
strains were able to efficiently replicate in HCC cell lines.
Consistent with our previously reported data, the titers in PHH
were about 3 logs lower. In PH5CH8 cells, both viruses replicated
to a similar extent as in the cancer cell lines analyzed. Although
the titers were lower at earlier time-points post-infection (8–
16 hours) than those observed in HepG2 and Huh-7, titers at
24 hours post-infection were similar, indicating a more efficient
ability of PH5CH8 cells to support viral replication in comparison
to non-transformed primary hepatocytes. We have previously
shown that resistance to VSV could be partially ascribed to the
ability of PHH to mount an efficient innate immune response
upon viral infection, while HCC cells have lost the capacity to
induce IFN and, therefore, have increased permissiveness to VSV
[9]. The ability of PH5CH8 to proliferate in vitro, was assessed by
MTT assay and expression of G1-phase cyclins (cyclin D1) and
cyclin-dependent kinases (CDK4). Immortalization by the SV40
large T antigen induces active cell proliferation in PH5CH8 to a
level comparable to HCC cells (Fig. 1B). Furthermore, expression
levels of cyclin D1 and CDK were increased compared to PHH
(Fig. 1C). In order to verify the IFN response in PH5CH8 towards
VSV, we have performed a dual luciferase assay using an IFN-b
promoter (Fig. 2A). Transfection of synthetic dsRNA (Poly I:C)
was able to trigger promoter activity in PH5CH8 to levels
comparable to those in PHH, as already described by Kato and
colleagues [27]. Additionally, in PH5CH8 cells, the IFN promoter
was efficiently activated upon infection with the IFN-inducing
mutant VSV-M51R. Pre-treatment with IFN induced protection
from VSV infection in PH5CH8 and PHH with reduction of viral
titers by approximately 2 logs. In contrast, IFN-mediated
repression of VSV replication was less efficient in HepG2 and
Huh-7 cells (Fig. 2B). Our results indicate that immortalized
hepatocytes retain a closer phenotype to PHH in terms of innate
immunity.
Influence of cell cycle on VSV replication
Our results so far indicated that the acquisition of proliferating
activity by hepatocytes might favour VSV permissiveness. To
Figure 6. Cell type specificity of the CDK4 inhibitor. A) PH5CH8 and Huh-7 cells were treated with DMSO or CDK4 inhibitor at different
concentrations. Infection with VSV-wt was performed at an MOI of 0.1 for 24 hr. Viral titers were determined by TCID50. Data represent the average of
three independent experiments 6 standard deviation. B) Protein expression of CDK4, cyclin D1 and Akt in the lysates of the above described
experiment was performed by Western blot analysis.
doi:10.1371/journal.pone.0010988.g006
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Figure 7. Cell cycle arrest by siRNA. A) Cells were transfected without siRNA, with scramble siRNA (scramb) or with siRNA against cyclin D1 or
cyclin-kinase (CDK4). Forty-eight hours post-transfection cells were infected with VSV-wt at an MOI of 0.1 for 24 hours. Results show the average of at
least three independent experiments. B) Mock-infected lysates from PH5CH8 and Huh-7 cells of the experiment describe above are shown for the
Oncolytic VSV and HCC
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investigate the contribution of cell cycle and proliferation towards
VSV replication, we treated the HCC cell lines, HepG2 and Huh-
7, and the immortalized hepatocytes, PH5CH8, with a panel of
different chemical compounds that are able to block the cell cycle
at different stages (Fig. 3). The CDK inhibitor roscovitine induced
only a slight inhibition of viral replication in HepG2 and Huh-7.
Early S-phase arrest induced by aphidicolin had no impact on
VSV permissiveness in all cell lines tested. A CDK4 inhibitor
reduced viral titers only in PH5CH8 cells (Fig. 4A). In addition to
specific cell cycle inhibitors, we have also included a PI3K
inhibitor (LY294002) and an AKT inhibitor (AKT IV) due to
previous reports indicating that AKT is responsible for activation
of the viral P protein by phosphorylation [28]. Pre-treated cultures
were infected with VSV-wt at an MOI of 1 in the presence of fresh
inhibitors for 24 hours. Only the AKT IV inhibitor was able to
attenuate viral growth in all the cell lines tested, whereas the PI3K
inhibitor revealed no impact on viral replication (Fig. 4A).
Efficiency of cell cycle inhibitors was tested by MTT cell
proliferation assay. Cell growth in treated cells was evaluated in
comparison to mock-treated controls. Significant decrease in
proliferation rates was observed in all cell lines after treatment
(Fig. 4B). The observation that the impact of cell cycle inhibitors
on VSV replication was marginal in our cellular model argues that
cell cycle progression is not involved in regulating VSV
permissiveness. For all inhibitors, a G1 cell cycle arrest and a
corresponding decrease of phase S and G2/M (p,0.01) could be
observed by flow cytometry, as shown for the HCC cell line Huh-7
(Fig. 4C). For instance, a G1 cell cycle arrest was readily detectable
ranging between 59.661.1% (Rosco) to 8260.1% (Aphid) if
compared to DMSO (5360.5%). After roscovitine treatment, the
reduction of the G2/M cell fraction was less prominent if
compared to the effect of the administration of other inhibitors.
This is in agreement with previous data showing that roscovitine
causes a cell cycle arrest in G1 as well as in G2/M (Fig. 4C).
Additionally, we also tested higher concentrations of most of the
drugs used to block cell cycle. Ly294002 and aphidicolin did not
show cytotoxicity nor viral inhibition even at very high doses.
Roscovitine instead decreased viral titers at concentrations 2 to 4
fold higher that the one used to block cell cycle but, as well as
AKT IV and CDK4 inhibitors, displayed toxic effects (Fig. 5). The
decreased phosphorylation of AKT observed especially in
PH5CH8 cells (and in HCCs when applied at higher doses) upon
treatment with the CDK4 inhibitor, might explain the effect of the
CDK4 inhibitor on VSV replication and, as reported for AKT IV
inhibitor, addresses to unspecific activity of this drug (Fig. 6).
To further prove that VSV replication occurs independently of
cell cycle, we used RNA interference (Fig. 7A and B). A G1 cell
cycle arrest could also be observed after incubation of Huh-7 cells
with siRNA targeting CDK4 and cyclin D1 or control siRNA
(Fig. 7C). Here, neither the knockdown of cyclin D1 nor CDK4
influences viral titers in HepG2, Huh-7 or PH5CH8 cells
reinforcing the argument for cell cycle independent replication
of VSV.
VSV replication is not affected by inhibition of mTOR
VSV growth has recently been reported to be dependent on
cellular translation in T-lymphocytes, as demonstrated by
impaired replication in the absence of mTOR and/or eIF4E
activation [10]. We therefore analyzed the role of translation
initiation in HCC cell lines and immortalized hepatocytes in the
support of VSV replication. Rapamycin, the inhibitor of mTOR,
was applied at increasing concentrations overnight and cultures
were infected with VSV-wt at an MOI of 0.1 for 24 hours in the
presence of fresh inhibitor. Rapamycin pre-treatment did not
significantly alter viral replication, even when administered at high
doses (up to 500 nM) (Fig. 8A). To determine whether rapamycin
has an enhancing activity on VSV replication at earlier time points
post-infection, we performed the assay with VSV-wt at an MOI of
0.1 for 8 hours in the presence of 50 nM rapamycin. We observed
a slight increase in viral titers in rapamycin-treated cells, but
differences were not statistically significant (Fig. 8B). The activity
of rapamycin was assessed by inhibition of the phosphorylation
status of the mTOR substrate S6K (p70 ribosomal protein S6
kinase) and by MTT cell proliferation assay. In all cell lines,
rapamycin induced efficient inhibition of mTOR, as demonstrated
by the distinct dephosphorylation of the mTOR target S6K
(Fig. 8C) and a significant reduction in cell growth (Fig. 8D). When
we analyzed eIF4E activation, we observed that rapamycin had
only a marginal influence on eIF4E phosphorylation in PH5CH8
and Huh-7 cells, whereas in HepG2 cells de-phosphorylation of
eIF4E was observed when higher rapamycin doses were used
(Fig. 8C).
Initiation factors eIF4E and eIF2Be are not necessary for
VSV replication
Our aim was to examine whether key players in protein
synthesis signaling are important determinants for VSV replica-
tion. To determine whether activation of eIF4E contributes to
VSV replication, we induced eIF4E de-phosphorylation by the
treatment with the MNK1 inhibitor, CGP57380. In fact MNKs,
and not mTOR in HCC, are essential for eIF4E phosphorylation
[29]. Cells were pre-treated with MNK1 inhibitor for about
16 hours followed by VSV infection at an MOI of 0.1. Infection
was performed in the presence of freshly-added inhibitor, and viral
titers were determined at 24 hours post-infection. VSV replication
was neither affected in non-neoplastic hepatocytes nor in HCC cell
lines (Fig. 9A). The phosphorylation state of eIF4E upon MNK1
inhibitor treatment was monitored in uninfected cells by Western
Blot analyses (Fig. 8B). Although no changes in viral titers were
observed, treatment of uninfected cells with MNK1 inhibitor
drastically reduced the amount of the phosphorylated form of
eIF4E. This change in eIF4E phosphorylation status was achieved
at different concentrations according to the different cell lines
(Fig. 9B). MNK1 inhibitor significantly decreased cell growth rates
at the highest dose used (40 mM) in all the cell lines tested (Fig. 9C).
At higher concentrations of MNK1 inhibitor but not of
rapamycin, we observed a reduction in viral titers; however, this
reduction is due to an unspecific activity, which occurred in
parallel with cyctotoxicity from the high dose of inhibitor applied
(Fig. 10).
Concomitant inhibition of mTOR and MNK1 has been
reported to efficiently suppress cell proliferation and protein
synthesis in prostate cancer cells [19]. We therefore tested the
hypothesis that inhibition of eIF4E phosphorylation might also
reinforce the effect of rapamycin on protein translation in our cell
model and consequently perturbs permissiveness to VSV infection.
First, we measured proliferation of our cell lines in the presence of
both inhibitors by MTT proliferation assay. Rapamycin and
MNK1 inhibitor only partially decreased proliferation rates when
administered alone. The inhibitory effect was more pronounced
expression of cyclin D1 and CDK4. C) FACS analysis of cell cycle arrest in Huh-7 cells upon treatment with siRNA targeting CDK4 and cyclin D1 or
control siRNA (SCR). Experiments were conducted at least three times and triplicate values of one experiment are shown as representative (p,0.001).
doi:10.1371/journal.pone.0010988.g007
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when the inhibitors were supplied together (Fig. 11A) as described
by Bianchini and colleagues [19]. Both inhibitors maintained their
specific effects on protein phosphorylation after prolonged
incubation (16–24 hours) (Fig. 11B). Moreover, the impact of
concomitant inhibition of mTOR and MNK1 on VSV growth
was analyzed. Cells pre-treated with rapamycin (50 nM) and
MNK1 inhibitor (20 mM), administered alone or in combination,
were infected with VSV-wt at an MOI of 0.1 for twenty-four
hours. Viral titers obtained in mock-treated cultures were
comparable to those in treated cells, with no appreciable
Figure 8. Rapamycin activity on VSV replication. A) HepG2, Huh-7 and PH5CH8 cells were incubated overnight with increasing concentrations
of rapamycin (20, 100 and 500 nM), or in the case of the controls, DMSO was added. VSV infection was performed at an MOI of 0.1 for 24 hours in the
presence of fresh inhibitor. The viral titers shown are the average of three independent experiments. B) All cell lines were treated with 50 nM of
rapamycin as described above and infected with VSV-wt at an MOI of 0.1. Viral titers were determined at 8 hours post-infection. The data represent at
least two independent experiments 6 standard deviation. C) Cell lysates of mock- and rapamycin-treated cells were analysed by Western blot for
detection of the phosphorylated forms of kinase p70S6k and eIF4E and their corresponding base-line expression. D) MTT proliferation assay in mock-
treated (DMSO) and rapamycin-treated (RAPA) cultures. Data represent the mean of at least three independent experiments 6 standard deviation
(* p, 0.05; *** p,0.001).
doi:10.1371/journal.pone.0010988.g008
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differences (Fig. 11C). In order to assess the possibility of
phosphorylation-independent involvement of eIF4E, HCC cells
and immortalized hepatocytes were treated for 72 hours with
siRNA targeting eIF4E and S6K. RNA interference of eIF4E
resulted in a drastic decrease of the corresponding protein in all
the cell lines tested (Fig. 12A). VSV infection at an MOI of 0.1 was
performed in mock-, control siRNA- and eIF4E siRNA-transfect-
ed cells and viral titers were determined 8 hours post-infection.
Remarkably, VSV replication was not affected by reduced
expression of eIF4E (Fig. 12A). Similarly, siRNA knock-down of
the mTOR substrate S6K in HCC and immortalized hepatocytes
resulted in an efficient knockdown of S6K, while no impact of the
S6K depletion on VSV replication was observed (Fig. 12B).
Increased levels of eIF2Be are likely to augment permissiveness
of transformed MEFs to VSV [11]. Therefore, we tested the role
of eIF2Be subunit in HCC and non-neoplastic hepatocyte cell
lines. HepG2, Huh-7 and PH5CH8 cells were transfected with
siRNA specifically targeting eIF2Be and subjected to viral
infection with VSV-wt. Knockdown of eIF2Be expression was
monitored by Western blot analyses (Fig. 13A). HCC cells and
non-neoplastic hepatocytes, exhibiting a strong reduction in
eIF2Be protein expression did not show a corresponding reduction
Figure 9. VSV infection does not depend on the phosphorylation status of eIF4E. A) Cell cultures, pre-treated with MNK1 inhibitor as
described above, were infected with VSV-wt at MOI of 0.1 in the presence of fresh inhibitor. Titers were determined by TCID50 at 24 hours post-
infection. Data represent the average of at least three independent experiments 6 standard deviation (SD) B) Cells were pre-treated with DMSO or
the MNK1 inhibitor (CGP57380, Calbiochem) at increasing concentrations for about 36 hours. Phosphorylation of eIF4E was analyzed by Western blot
analyses using 100 mg of cell lysates. C) MTT assay on HCC and PH5CH8 cell lines treated with 40 mM of MNK1 inhibitor (CGP57380) are shown.
Results are the average of three independent experiments 6 SD (* p,0.05).
doi:10.1371/journal.pone.0010988.g009
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in viral titers compared to mock- or negative control-transfected
cells (Fig. 13B).
Discussion
Impairments of the type I IFN signaling pathway are thought to
be the responsible mechanism contributing to the tumor specificity
of VSV replication, explaining its attenuated phenotype in PHH
when compared to human HCC cell lines [9]. Although
production of IFN plays an important role in host defense,
increasing evidence indicates that some additional cellular factors,
together with the defective IFN response in cancers cells, might
govern the oncolytic specificity of VSV [9]. During malignant
transformation, normal growth control mechanisms are partially
or completely ablated, thereby inducing abnormal proliferation.
While hepatocytes rarely divide in healthy liver tissue, the
abrogation of cell cycle checkpoints occurs during tumorigenesis.
Recently, it has been shown that VSV infection in primary T-
lymphocytes depends on G0/G1 transition and requires transla-
tion initiation [10]. For this reason, and because of the notion that
a number of different viruses interact with the cell cycle machinery
[30,31,32], we have investigated the influence of the cell-cycle and
cellular protein translation on VSV replication in HCC. In
addition to HCC cell lines, we investigated the PH5CH8 cell line
derived from human hepatocytes immortalized with the simian
virus 40 (SV40) large T antigen [33,34]. Since PH5CH8 cells, in
contrast to HCC, maintain an intact IFN system [27,35], they
represent an ideal cell line for investigating the presence of
additional factors contributing to the differential permissiveness to
VSV in primary versus non-neoplastic transformed cells. PH5CH8
cells efficiently support growth of VSV-wt and the IFN-inducing
mutant, VSV-M51R, but in contrast to HCC cells, they are also
able to mount an IFN response upon viral infection with VSV-
M51R or stimulation with synthetic dsRNA (Poly I:C), as
demonstrated by a reporter gene assay using the IFN-b promoter.
PH5CH8 cells are also protected against VSV infection when pre-
treated with IFN, indicating a functional IFN signaling pathway.
Our results indicate that PH5CH8 cells retain a closer phenotype
to primary hepatocytes in terms of innate immunity, but have
acquired the ability to proliferate in culture with similar expression
levels of G1-phase cyclins and cyclin-dependent kinases as in HCC
cells. Based on this observation, we hypothesized that the
acquisition of proliferating activity and, therefore, increased
protein translation activity, might favor VSV permissiveness, as
reported in primary T-lymphocytes [10]. Moreover, a recent
publication indicates that disruption of cell cycle in normal rat
kidney cells (NRK) is important for VSV ability to kill cells [36].
Chakraborty and colleagues report that VSV infection in NRK
cells results in significant cell death during metaphase. To
determine whether the same principle applied to our cells, HCC
and PH5CH8 cells were treated with a panel of different chemical
compounds to block the cell cycle. In addition to specific cell cycle
inhibitors, we have also included the PI3K inhibitor, LY294002,
and an AKT inhibitor, due to previous reports indicating that
AKT activity is necessary for VSV replication [28]. Although we
confirmed the inhibitory property of the AKT inhibitor on viral
growth, none of the other inhibitors demonstrated an attenuation
of VSV replication in the cell lines tested. The CDK4 inhibitor
was an exception, attenuating VSV in PH5CH8 cells at the lowest
concentration. However, this effect could be due to the influence
of the CDK4 inhibitor on AKT activity, as measured by AKT
phosphorylation, with PH5CH8 being more sensitive than the
other cell lines investigated. In fact, at the lowest dose applied,
HCC cell lines were successfully blocked in G1 phase but viral
titers were not affected. Interestingly, while the AKT IV inhibitor
substantially impaired viral growth, the upstream PI3K inhibitor
LY294002 had no effect on VSV growth despite successful de-
phosphorylation of AKT (data not shown) and despite inducing
G1 phase arrest. We hypothesized that this contradiction was due
to the fact that the AKT IV inhibitor is not specific for AKT, but
instead has some secondary function. This observation was
recently confirmed by Dunn and colleagues [37], who stated that
AKT IV is, in fact, a broad-spectrum anti-viral compound with a
mechanism differing from its previously reported effect on the
PI3K/AKT pathway. These data support our conclusion that the
PI3K/AKT pathway is of little relevance to VSV replication.
We then confirmed the independence of VSV growth on cell-cycle
phase by using small interfering RNA (siRNA) to specifically target
cyclin D1 and cyclin-dependant kinases (CDK) 4. Ablation or
reduction of the expression of these cell cycle components did not
result in attenuation of VSV replication in any cell line tested but
Figure 10. Effects of high doses of MNK inhibitor and
rapamycin on VSV replication. HCC cells (HepG2 and Huh-7) and
immortalized human hepatocytes (PH5CH8) were mock-treated (DMSO)
or treated with increasing concentrations of MNK inhibitor and
rapamycin until the appearance of cytotoxicity. Cultures were infected
with VSV-wt at an MOI of 0.1 and viral titers were determined 24 hr
post-infection by TCID 50. Data represent the average of three
independent experiments.
doi:10.1371/journal.pone.0010988.g010
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significantly arrested cells in G1. We therefore concluded that,
contradictory to what has been seen in primary T-lymphocytes and
normal rat kidney cells, cell proliferation is not a key player in
supporting VSV replication in HCC. According to Chakraborty and
colleagues, VSV preferentially kills cells that undergo mitosis.
Accordingly, a block in G1 phase should have reduced cell
susceptibility to VSV-mediated cell death in mitosis as hypothesized
from the authors in the case of T-lymphocytes. In our study, despite a
successful arrest of cell cycle prior to entry into mitosis, we did not
observed a reduction in viral titers, based on the general assumption
that oncolytic activity is coupled to viral replication. This observation
emphasizes once more the importance of cell-type specificity. Kidney
cells, as T-lymphocytes, are normal primary cells with a very different
molecular make-up from cancer cells, especially concerning their
ability to mount an efficient innate immune response, which is
irreparably compromised during malignant transformation. Trans-
lation rates are particularly robust in cancer cells, and deregulation of
the PI3K/AKT/mTOR pathway was reported to contribute to
cancer development and maintenance [38]. In some malignant
neoplasms, including HCC and derived cell lines, mTOR is highly
activated [39] [2,12]. Arrest of T cells in G1 phase and inhibition of
protein synthesis via mTOR and the elongation factor eIF4E activity,
inhibits VSV replication [10]. Interestingly however, VSV infection
results in reduction of eIF4E phosphorylation, shortly preceding the
shut-off of host protein synthesis in tumor cell lines [40].
Our results indicate that rapamycin had no effect on VSV
infection in HCC cells and immortalized hepatocytes. Interesting-
ly, rapamycin potently inhibited phosphorylation of S6K kinase,
Figure 12. RNA interference assay for eIF4E and S6K. HCC and PH5CH8 cells were transfected with siRNA for eIF4E A) or S6K B) at a
concentration of 100 nM. As controls, cells were transfected in parallel with siRNA scramble or mock-transfected. At 72 hours post-transfection, cells
were infected with VSV-wt using an MOI of 0.1 and viral titers were determined 8 hours post-infection. Results are the average of three independent
experiments, and error bars indicate the standard deviation. Mock-infected cultures were used to control the efficiency of the mRNA silencing by
Western blot analyses. Western blot analysis was performed for each experiment.
doi:10.1371/journal.pone.0010988.g012
Figure 11. Effects of concomitant inhibition of mTOR and MNK on VSV proliferation. Cells were mock-treated (DMSO) or treated with
rapamycin at 50 nm, MNK1 inhibitor at 20 mM, alone or together as indicated. A) Cell proliferation assays were performed using the MTT assay.
Representative results of at least two independent experiments are shown. B) Western blot analysis of lysates obtained by PH5CH8 and HepG2 cell
lines mock-treated (DMSO) or treated with rapamycin (RAPA), MNK inhibitor (MNK in) alone or in combination (RAPA+MNK in). The levels of S6K and
eIF4E phosphorylated forms were monitored after inhibitor treatment. C) Cells were infected with VSV-wt at an MOI of 0.1 for 24 hours. Viral titers
represent the mean 6 standard deviation of three experiments.
doi:10.1371/journal.pone.0010988.g011
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while the phosphorylation status of eIF4E remained almost
unaffected. The inability of rapamycin to block activation of
eIF4E could explain the efficient replication of VSV in the
presence of the inhibitor. However, effective de-phosphorylation
of eIF4E by the MNK1 inhibitor, CGP5738, did not lead to
attenuation of VSV growth in both HCC cell lines and non-
neoplastic hepatocytes, and, furthermore, reduction of eIF4E by
RNA interference did not affect virus growth. In an attempt to
identify other translational factors involved in VSV permissiveness
in HCC, we analyzed the role of the eukaryotic initiation factor 2B
(eIF2B). The expression of the e-subunit of eIF2B is up-regulated
in association with increased cell growth and is linked to
oncogenesis [41]. Although increased levels of eIF2Be render
transformed MEFs susceptible to VSV [11], knock-down of
eIF2Be mRNA in HCC cells did not alter their permissiveness to
viral infection. We speculate that this discrepancy can be ascribed
to the fact that the immortalization process in MEFs is associated
with a selective block of type I IFN induction [42].
We conclude from our observations that in HCC, enhanced
cap-dependent translation and increased proliferation rates are
negligible for VSV replication. This finding is in agreement with
the observation that VSV selectively induces de-phosphorylation
of eIF4E prior to initiation of general translational shut-off,
indicating that viral replication does not necessarily rely on active
cellular translational pathways [40]. Our results clearly indicate
that the mechanisms supporting VSV oncolysis are cell-type
specific, and the factors governing VSV permissiveness in T-
lymphocytes and normal kidney cells are not applicable to HCC.
We can only speculate that these differences can be attributed to
substantial differences in viral infection mechanisms in primary
cells versus cancer cells. This observation is very important if we
consider the possible effects on therapeutic outcomes. Recently,
novel antineoplastic agents with strong anti-proliferative effects
have been objects of several pre-clinical and clinical studies in
treatment of HCC [43,44,45]. Based on the results presented here,
we can anticipate further studies investigating the combination of
anti-proliferative drugs with VSV oncolytic therapy, since no
decrease in VSV replication was observed upon inhibition of
proliferation or translation.
Mounting evidence suggests that liver cancer stem cells are
responsible for HCC initiation. Due to their resistance to
chemotherapy and radiation, they are responsible for recurrent
tumor formation and account for the failure of conventional
therapies [46,47]. Cancer initiating cells (CIC) have reduced
Figure 13. RNA interference assay for eIF2B epsilon (eIF2Be). A) Western blot analysis of mock-infected cultures was performed for each
experiment to assess the efficiency of RNA silencing. B) HepG2, Huh-7 and PH5CH8 cells were transfected with siRNA for eIF2Be at a concentration of
100 nM. As controls, cells were transfected in parallel with control siRNA or mock-transfected. At 72 hours post-transfection, cells were infected with
VSV-wt using an MOI of 0.1 for 8 hours. Results are the average of three independent experiments and error bars indicate the standard deviation.
doi:10.1371/journal.pone.0010988.g013
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differentiation potential and possess less proliferative capacity.
Since we have concluded that active proliferation in HCC is not
required for VSV infection, there is the potential that VSV could
be effective in eradicating CIC. Although a recent report indicated
that VSV failed to successfully infect neuroblastoma or breast
cancer CICs [48], it remains to be seen whether or not HCC CICs
are permissive to VSV replication. This will be an interesting focus
of future experimental investigations.
In conclusion, the application of oncolytic viruses as novel
agents in cancer therapy should be based on the understanding of
cancer cell biology. Identification of internal cell factors that
mediate tumor-specific viral growth is essential for the rational
design of viral vectors with potent and selective anti-tumor activity,
while minimizing normal tissue toxicity. Combination therapy
represents a promising avenue for ongoing translation of oncolytic
viruses into clinical practice [49] [50,51]. In this work, we have
provided indications of a potential combination of VSV with anti-
proliferative drugs as a rational therapeutic option for HCC.
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